Cutting-Edge Advancements in the Antibiotics-Gut Microbiota-Urinary Tumour Axis

References

[1] D. Hanahan, “Hallmarks of Cancer: New Dimensions,” Cancer Discovery 12, no. 1 (2022): 31-46, https://doi.org/10.1158/2159-8290.Cd-21-1059.

[2] D. Li, R. Wu, Q. Yu, et al., “Microbiota and Urinary Tumor Immunity: Mechanisms, Therapeutic Implications, and Future Perspectives,” Chinese Journal of Cancer Research 36, no. 6 (2024): 596-615, https://doi.org/10.21147/j.issn.1000-9604.2024.06.03.

[3] K. Zuo, C. Fang, Y. Gao, et al., “Suppression of the Gut Microbiota-Bile Acid-FGF19 Axis in Patients With Atrial Fibrillation,” Cell Proliferation 56, no. 11 (2023): e13488, https://doi.org/10.1111/cpr.13488.

[4] D. C. Feng, W. Z. Zhu, J. Wang, et al., “The Implications of Single-Cell RNA-Seq Analysis in Prostate Cancer: Unraveling Tumor Heterogeneity, Therapeutic Implications and Pathways Towards Personalized Therapy,” Military Medical Research 11, no. 1 (2024): 21, https://doi.org/10.1186/s40779-024-00526-7.

[5] F. Shao, Z. Wang, L. Ye, et al., “Basic Helix-Loop-Helix ARNT Like 1 Regulates the Function of Immune Cells and Participates in the Development of Immune-Related Diseases,” Burns & Trauma 13 (2025): tkae075, https://doi.org/10.1093/burnst/tkae075.

[6] X. Zhang, R. Zhu, D. Yu, J. Wang, Y. Yan, and K. Xu, “Single-Cell RNA Sequencing to Explore Cancer-Associated Fibroblasts Heterogeneity: “Single” Vision for “Heterogeneous” Environment,” Cell Proliferation 57, no. 5 (2024): e13592, https://doi.org/10.1111/cpr.13592.

[7] D. Feng, J. Wang, R. Wu, and D. Li, “Re: Immune System and Intestinal Microbiota Determine Efficacy of Androgen Deprivation Therapy Against Prostate Cancer,” European Urology 85, no. 5 (2024): 498-499, https://doi.org/10.1016/j.eururo.2024.01.025.

[8] H. Hui, Z. Wang, X. Zhao, et al., “Gut Microbiome-Based Thiamine Metabolism Contributes to the Protective Effect of One Acidic Polysaccharide From Selaginella Uncinata (Desv.) Spring Against Inflammatory Bowel Disease,” Journal of Pharmaceutical Analysis 14, no. 2 (2024): 177-195, https://doi.org/10.1016/j.jpha.2023.08.003.

[9] H. Yu, H. Xu, X. Yang, et al., “Gut Microbiota-Based Pharmacokinetic-Pharmacodynamic Study and Molecular Mechanism of Specnuezhenide in the Treatment of Colorectal Cancer Targeting Carboxylesterase,” Journal of Pharmaceutical Analysis 13, no. 9 (2023): 1024-1040, https://doi.org/10.1016/j.jpha.2023.06.012.

[10] H. Sadrekarimi, Z. R. Gardanova, M. Bakhshesh, et al., “Emerging Role of Human Microbiome in Cancer Development and Response to Therapy: Special Focus on Intestinal Microflora,” Journal of Translational Medicine 20, no. 1 (2022): 301, https://doi.org/10.1186/s12967-022-03492-7.

[11] B. Roje, B. Zhang, E. Mastrorilli, et al., “Gut Microbiota Carcinogen Metabolism Causes Distal Tissue Tumours,” Nature 632, no. 8027 (2024): 1137-1144, https://doi.org/10.1038/s41586-024-07754-w.

[12] M. Fidelle, C. Rauber, C. Alves Costa Silva, et al., “A Microbiota-Modulated Checkpoint Directs Immunosuppressive Intestinal T Cells Into Cancers,” Science 380, no. 6649 (2023): eabo2296, https://doi.org/10.1126/science.abo2296.

[13] L. F. Mager, R. Burkhard, N. Pett, et al., “Microbiome-Derived Inosine Modulates Response to Checkpoint Inhibitor Immunotherapy,” Science 369, no. 6510 (2020): 1481-1489, https://doi.org/10.1126/science.abc3421.

[14] N. Pernigoni, E. Zagato, A. Calcinotto, et al., “Commensal Bacteria Promote Endocrine Resistance in Prostate Cancer Through Androgen Biosynthesis,” Science 374, no. 6564 (2021): 216-224, https://doi.org/10.1126/science.abf8403.

[15] G. Lachance, K. Robitaille, J. Laaraj, et al., “The Gut Microbiome-Prostate Cancer Crosstalk Is Modulated by Dietary Polyunsaturated Long-Chain Fatty Acids,” Nature Communications 15, no. 1 (2024): 3431, https://doi.org/10.1038/s41467-024-45332-w.

[16] J. P. Motta, J. L. Wallace, A. G. Buret, C. Deraison, and N. Vergnolle, “Gastrointestinal Biofilms in Health and Disease,” Nature Reviews. Gastroenterology & Hepatology 18, no. 5 (2021): 314-334, https://doi.org/10.1038/s41575-020-00397-y.

[17] S. Okumura, Y. Konishi, M. Narukawa, et al., “Gut Bacteria Identified in Colorectal Cancer Patients Promote Tumourigenesis via Butyrate Secretion,” Nature Communications 12, no. 1 (2021): 5674, https://doi.org/10.1038/s41467-021-25965-x.

[18] T. Irrazabal, A. Belcheva, S. E. Girardin, A. Martin, and D. J. Philpott, “The Multifaceted Role of the Intestinal Microbiota in Colon Cancer,” Molecular Cell 54, no. 2 (2014): 309-320, https://doi.org/10.1016/j.molcel.2014.03.039.

[19] S. Davidsson, A. L. Ohlson, S. O. Andersson, et al., “CD4 Helper T Cells, CD8 Cytotoxic T Cells, and FOXP3(+) Regulatory T Cells With Respect to Lethal Prostate Cancer,” Modern Pathology 26, no. 3 (2013): 448-455, https://doi.org/10.1038/modpathol.2012.164.

[20] C. Coutzac, J. M. Jouniaux, A. Paci, et al., “Systemic Short Chain Fatty Acids Limit Antitumor Effect of CTLA-4 Blockade in Hosts With Cancer,” Nature Communications 11, no. 1 (2020): 2168, https://doi.org/10.1038/s41467-020-16079-x.

[21] K. Wu, Y. Li, K. Ma, et al., “The Microbiota and Renal Cell Carcinoma,” Cellular Oncology 47, no. 2 (2023): 397-413, https://doi.org/10.1007/s13402-023-00876-9.

[22] L. Derosa, M. D. Hellmann, M. Spaziano, et al., “Negative Association of Antibiotics on Clinical Activity of Immune Checkpoint Inhibitors in Patients With Advanced Renal Cell and Non-Small-Cell Lung Cancer,” Annals of Oncology 29, no. 6 (2018): 1437-1444, https://doi.org/10.1093/annonc/mdy103.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.